Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials

Immune checkpoint inhibitors (ICI) targeting the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have significantly improved the outcome of metastatic non-small cell lung cancer (NSCLC).[1,2] Patients with NSCLC treated with ICI, either as monotherapy or in combination with chemotherapy, are surviving longer as compared to patients receiving chemotherapy alone,[3 –9] with 5-year overall survival (OS) rates as high as 15-30%.[10,11]

Source: Radiotherapy and Oncology - December 6, 2023 Category: Radiology Authors: Ilinca Popp, Rianne D.W. Vaes, Lotte Wieten, Sonja Adebahr, Lizza Hendriks, Elham Bavafaye Haghighi, Juliette Degens, Henning Sch äfer, Christine Greil, Stéphanie Peeters, Cornelius F. Waller, Ruud Houben, Gabriele Niedermann, Justyna Rawluk, Eleni Gkik Tags: Original Article Source Type: research